# Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

> **NCT06252285** · PHASE3 · TERMINATED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 6300 (actual)

## Conditions studied

- RSV Immunisation

## Interventions

- **BIOLOGICAL:** RSVt Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06252285
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-06
- **Primary completion:** 2025-12-04
- **Final completion:** 2025-12-04
- **Target enrollment:** 6300 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06252285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06252285, "Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06252285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*